(Q30961090)

27 June 2017

title

Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials (English)

1 reference

27 June 2017

Michael C Smith

1

1 reference

27 June 2017

Franca Centorrino

series ordinal

2

1 reference

27 June 2017

Jeffrey A Welge

series ordinal

3

1 reference

27 June 2017

Michelle A Collins

series ordinal

4

1 reference

27 June 2017

publication date

1 October 2004

1 reference

27 June 2017

1 reference

27 June 2017

volume

5

1 reference

27 June 2017

issue

5

1 reference

27 June 2017

page(s)

746-751

1 reference

Patients with refractory seizures.

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Management of epilepsy in adolescents and adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Valproate in the treatment of acute mania. A placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

New formulations of drugs in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Divalproex-ER pharmacokinetics in older children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Migraine prophylaxis with divalproex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Divalproex sodium in migraine prophylaxis: a dose-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

Nonspecific effects in longitudinal studies: impact on quality of life measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.007

10.1016/J.YEBEH.2004.07.007

7 January 2021

Identifiers

DOI

1 reference

27 June 2017

1 reference